As PBMs face threats in Washington, industry trade group poured millions more into lobbying
Perhaps no industry in healthcare has seen its political fortunes change faster than PBMs over the last two years.
It’s been just more than a year since Democrats in DC focused on the pharma-targeting Inflation Reduction Act and its drug price reforms. Pharmacy benefit managers quickly became the next item on the target list for lawmakers — from both parties — who want to bring down healthcare costs and increase transparency.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
